Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford University Innovation Incubator unveils with new deal on equity and access to finance through the OUI Future Fusion programme.

None © Oxford University Innovation

The Oxford University Innovation (OUI) Incubator has relaunched with a new deal on equity and access to finance for Oxford University startups, after an extensive overhaul and refurbishment under its new manager, Catherine Spence.

The incubator, which has created 30 companies since launching in 2011 including verification and background check platform Onfido, has reduced the equity stake it asks from potential portfolio startups by half down to 5%. In addition, the incubator has collaborated with early-stage investors to create a programme to provide robust and constructive early stage feedback as well as back startups with the initial cash they need to get wheels turning, called OUI Future Fusion.

Read more (Oxford University Innovation website)

Similar stories

University spinout PepGen awarded major financing to target Duchenne muscular dystrophy

Awards and Appointments General Innovation

PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company’s original seed investor.

Evox Therapeutics announces launch of strategic collaboration with the University of Oxford

General Innovation

Collaboration with world-renowned research centre to accelerate development of exosome therapies for rare diseases

BioEscalator’s resident biotech Base Genomics acquired by Exact Sciences

General Innovation

Oxford Sciences Innovation (OSI) recently announced the acquisition of its portfolio company, Base Genomics, by US-based early cancer diagnostic leaders, Exact Sciences, for $410m. The partnership will enable Base Genomics to significantly accelerate its clinical and commercial development here in Oxford, potentially unlocking a new era of preventative medicine and improved patient outcomes.

Comparison of five tests used to detect COVID-19 antibodies shows Siemens and Oxford assays met regulatory targets

Coronavirus COVID-19 Innovation Research

New research shows that, in a head-to-head comparison of five tests used to detect COVID-19 antibodies (known as ‘immunoassays’), an assay manufactured by Siemens and one developed by an academic partnership led by the University of Oxford had the most accurate results. The study is published in The Lancet Infectious Diseases.

QUOD enters partnership with Evotec

General Innovation Research

Evotec SE, a drug discovery and development solutions company, today announced a partnership agreement with the University of Oxford regarding access to biospecimens from the biobank Quality in Organ Donation (QUOD), an initiative of the Nuffield Department of Surgical Sciences (NDS) at the University of Oxford in close collaboration with the National Health Service Blood and Transplant (NHSBT) organisation in the UK.